Shiga toxin-producing Escherichia coli

  • Jenifer L. Jaeger
  • David W. K. Acheson


Shiga toxin-producing Escherichia coli (STEC) are emerging as a significant source of foodborne infectious disease in the developed world. Multistate outbreaks of E. coli O157 and non-O157 serogroups in the United States are facilitated by the centralization of food processing and distribution. Our ability to recognize the clonality of these clusters has been advanced by developments in molecular detection techniques and in the establishment of active surveillance practices. These studies have helped identify important risk factors for both sporadic and outbreak STEC infection, allowing us to develop appropriate prevention strategies. Identification of these factors is of critical importance because of the lack of adequate treatments available. This brief review of the literature discusses major developments in the epidemiology, pathogenesis, diagnosis, treatment, and prevention of STEC disease published in the past few years.


Fosfomycin Shiga Toxin Multiplex Polymerase Chain Reaction Assay Gnotobiotic Mouse Enterocyte Effacement 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References and Recommended Reading

  1. 1.
    Paton JC, Paton AW: Pathogenesis and diagnosis of Shiga toxin-producing Escherichia coli infections. Clin Microbiol Rev 1998, 11:450–479. This comprehensive review of Shiga toxin-producing E. coli infections focuses on the pathogenesis and diagnosis of these infections. Particular emphasis is placed on the role of Shiga toxins and other virulence factors of both O157 and non-O157 serotypes.PubMedGoogle Scholar
  2. 2.
    Nataro JP, Kaper JB: Diarrheagenic Escherichia coli. Clin Microbiol Rev 1998, 11:142–201. This thorough analysis of diarrheagenic E. coli is organized according to the five major types of E. coli: enterotoxigenic, enteropathogenic, enterohemorrhagic, enteroaggregative, and enteroinvasive. In each section, the authors review the pathogenesis, epidemiology, and diagnosis unique and essential to the type being addressed. The paper also includes a separate discussion of diffusely adherent E. coli.PubMedGoogle Scholar
  3. 3.
    Kaper JB, O’Brien AD, eds.: Escherichia coli O157:H7 and Other Shiga Toxin-Producing E. coli Strains. Washington, DC: ASM Press; 1998. This book contains the work presented at the Third International Symposium and Workshop on Shiga Toxin-Producing Escherichia coli Infections (VTEC ’97), held in Baltimore, Maryland, 22–26 June 1997. It is the definitive source on E. coli O157:H7 and other STEC strains and reveals the diversity of disciplines involved in the study of STEC. The epidemiology of STEC in humans and in food, and the bacterial and host factors of pathogenesis, diagnosis, and treatment, including vaccine development, are all addressed in this single volume.Google Scholar
  4. 4.
    Wang G, Doyle MP: Survival of enterohemorrhagic Escherichia coli O157:H7 in water. J Food Prot 1998, 61:662–667.PubMedGoogle Scholar
  5. 5.
    Kudva IT, Hunt CW, Williams CJ, et al.: Evaluation of dietary influences on Escherichia coli O157:H7 shedding by sheep. Appl Environ Microbiol 1997, 63:3878–3886.PubMedGoogle Scholar
  6. 6.
    Iwasa M, Makino S, Asakura H, et al.: Detection of Escherichia coli O157:H7 from Musca domestica (Diptera: Muscidae) at a cattle farm in Japan. J Med Entomol 1999, 36:108–112.PubMedGoogle Scholar
  7. 7.
    Bender JB, Hedberg CW, Besser JM, et al.: Surveillance for Escherichia coli O157:H7 infection in Minnesota by molecular subtyping. N Engl J Med 1997, 337:388–394. This study illustrates the power of pulsed-field gel electrophoresis in relation to its ability to link apparently unconnected cases into outbreaks.PubMedCrossRefGoogle Scholar
  8. 8.
    Rios M, Prado V, Trucksis M, et al.: Clonal diversity of Chilean isolates of enterohemorrhagic Escherichia coli from patients with hemolytic-uremic syndrome, asymptomatic subjects, animal reservoirs, and food products. J Clin Microbiol 1999, 37:778–781.PubMedGoogle Scholar
  9. 9.
    Schmidt H, Geitz C, Tarr PI, et al.: Non-O157:H7 pathogenic Shiga toxin-producing Escherichia coli: phenotypic and genetic profiling of virulence traits and evidence for clonality. J Infect Dis 1999, 179:115–123.PubMedCrossRefGoogle Scholar
  10. 10.
    Grif K, Karch H, Schneider C, et al.: Comparative study of five different techniques for epidemiological typing of Escherichia coli O157. Diagn Microbiol Infect Dis 1998, 32:165–176.PubMedCrossRefGoogle Scholar
  11. 11.
    Brudzinski L, Harrison MA: Influence of incubation conditions on survival and acid tolerance response of Escherichia coli O157:H7 and non-O157:H7 isolates exposed to acetic acid. J Food Prot 1998, 61:542–546.PubMedGoogle Scholar
  12. 12.
    Diez-Gonzalez F, Callaway TR, Kizoulis MG, et al.: Grain feeding and the dissemination of acid-resistant Escherichia coli from cattle. Science 1998; 281:1666–1668. This study investigates the phenomenon of acid-resistant E. coli. The authors raise the interesting possibility that feeding cattle a diet of hay before slaughter will diminish the virulence of E. coli O157:H7. This approach is fascinating, but more work is needed before it can be considered viable.PubMedCrossRefGoogle Scholar
  13. 13.
    Iijima Y, Matsumoto M, Higuchi K, et al.: Resistance to dryness of Escherichia coli O157:H7 strains from outbreak in Sakai City, Japan, 1996. Emerg Infect Dis 1998, 4:340–341.PubMedGoogle Scholar
  14. 14.
    McCarthy J, Holbrook R, Stephens PJ: An improved direct plate method for the enumeration of stressed Escherichia coli O157:H7 from food. J Food Prot 1998, 61:1093–1097.PubMedGoogle Scholar
  15. 15.
    Slutsker L, Ries AA, Maloney K, et al.: A nationwide case-control study of Escherichia coli O157:H7 infection in the United States. J Infect Dis 1998, 177:962–966. This collaborative study investigates the epidemiology of sporadic E. coli O157:H7 infection over a 2-year period across the United States. It enumerates risk factors for HUS, including the use of antimicrobial agents in children.PubMedGoogle Scholar
  16. 16.
    Bonnet R, Souweine B, Gauthier G, et al.: Non-O157:H7 Stx2-producing Escherichia coli strains associated with sporadic cases of hemolytic-uremic syndrome in adults. J Clin Microbiol 1998, 36:1777–1780.PubMedGoogle Scholar
  17. 17.
    Beutin L, Zimmermann S, Gleier K: Human infections with Shiga toxin-producing Escherichia coli other than serogroup O157 in Germany. Emerg Infect Dis 1998, 4:635–639.PubMedCrossRefGoogle Scholar
  18. 18.
    Morabito S, Karch H, Mariani-Kurkdjian P, et al.: Enteroaggregative, Shiga toxin-producing Escherichia coli O111:H2 associated with an outbreak of hemolytic-uremic syndrome. J Clin Microbiol 1998, 36:840–842.PubMedGoogle Scholar
  19. 19.
    Goldwater PN, Bettelheim KA: New perspectives on the role of Escherichia coli O157:H7 and other enterohaemorrhagic E. coli serotypes in human disease. J Med Microbiol 1998, 47:1039–1045.PubMedGoogle Scholar
  20. 20.
    Brooks HJ, Bettelheim KA, Todd B, et al.: Non-O157 Vero cytotoxin producing Escherichia coli: aetiological agents of diarrhoea in children in Dunedin, New Zealand. Comp Immunol Microbiol Infect Dis 1997, 20:163–170.PubMedCrossRefGoogle Scholar
  21. 21.
    Huppertz HI, Busch D, Schmidt H, et al.: Diarrhea in young children associated with Escherichia coli non-O157 organisms that produce Shiga-like toxin. J Pediatr 1996, 128:341–346.PubMedCrossRefGoogle Scholar
  22. 22.
    Starr M, Bennett-Wood V, Bigham AK, et al.: Hemolytic-uremic syndrome following urinary tract infection with enterohemorrhagic Escherichia coli: case report and review. Clin Infect Dis 1998, 27:310–315. This report of a case of HUS after urinary tract infection and review of 13 cases from the literature illustrates the danger of nonenteric infections with STEC leading to life-threatening complications.PubMedGoogle Scholar
  23. 23.
    Paton AW, Voss E, Manning PA, et al.: Shiga toxin-producing Escherichia coli isolates from cases of human disease show enhanced adherence to intestinal epithelial (Henle 407) cells. Infect Immun 1997, 65:3799–3805.PubMedGoogle Scholar
  24. 24.
    Abe A, Heczko U, Hegele RG, et al.: Two enteropathogenic Escherichia coli type III secreted proteins, EspA and EspB, are virulence factors. J Exp Med 1998, 188:1907–1916.PubMedCrossRefGoogle Scholar
  25. 25.
    Ebel F, Podzadel T, Rohde M, et al.: Initial binding of Shiga toxin-producing Escherichia coli to host cells and subsequent induction of actin rearrangements depend on filamentous EspA-containing surface appendages. Mol Microbiol 1998, 30:147–161.PubMedCrossRefGoogle Scholar
  26. 26.
    Kenny B, DeVinney R, Stein M, et al.: Enteropathogenic E. coli (EPEC) transfers its receptor for intimate adherence into mammalian cells. Cell 1997, 91:511–520. This study provides the first evidence of a bacterially encoded translocated protein in enteropathogenic E. coli. The authors determined the sequence of the intimin receptor and identified the presumed intimin binding site, two membrane-spanning domains, and the portion responsible for penetrating the host cell cytoplasm. This study has contributed greatly to our understanding of the pathogenesis of enteropathogenic E. coli and, subsequently, enterohemorrhagic E. coli.PubMedCrossRefGoogle Scholar
  27. 27.
    Paton AW, Manning PA, Woodrow MC, et al.: Translocated intimin receptors (Tir) of Shiga-toxigenic Escherichia coli isolates belonging to serogroups O26, O111 and O157 react with sera from patients with hemolytic-uremic syndrome and exhibit marked sequence heterogeneity. Infect Immun 1998, 66:5580–5586.PubMedGoogle Scholar
  28. 28.
    Dean-Nystrom EA, Bosworth BT, Moon HW, et al.: Escherichia coli O157:H7 requires intimin for enteropathogenicity in calves. Infect Immun 1998, 66:4560–4563.PubMedGoogle Scholar
  29. 29.
    Brunder W, Schmidt H, Karch H: EspP, a novel extracellular serine protease of enterohaemorrhagic Escherichia coli O157:H7 cleaves human coagulation factor V. Mol Microbiol 1997, 24:767–778.PubMedCrossRefGoogle Scholar
  30. 30.
    Acheson DWK, Reidl J, Zhang X, et al.: In vivo transduction with Shiga toxin 1-encoding phage. Infect Immun 1998, 66:4496–4498.PubMedGoogle Scholar
  31. 31.
    Matsushiro A, Sato K, Miyamoto H, et al.: Induction of prophages of enterohemorrhagic Escherichia coli O157:H7 with norfloxacin. J Bacteriol 1999, 181:2257–2260. In a series of experiments, these authors documented the effects of sublethal concentrations of the new quinolone norfloxacin on toxin production from E. coli O157:H7. They showed induction of prophage with subsequent increase in toxin gene copy number and a significant increase in toxin. They further revealed involvement of the RecA system, helping to explain the effect of inhibition of DNA synthesis on toxin elaboration.PubMedGoogle Scholar
  32. 32.
    Muniesa M, Jofre J: Abundance in sewage of bacteriophages that infect Escherichia coli O157:H7 and that carry the Shiga toxin 2 gene. Appl Environ Microbiol 1998, 64:2443–2448.PubMedGoogle Scholar
  33. 33.
    Plunkett G 3d, Rose DJ, Durfee TJ, et al.: Sequence of Shiga toxin 2 phage 933W from Escherichia coli O157:H7: Shiga toxin as a phage late-gene product. J Bacteriol 1999, 181:1767–1778.PubMedGoogle Scholar
  34. 34.
    Burland V, Shao Y, Perna NT, et al.: The complete DNA sequence and analysis of the large virulence plasmid of Escherichia coli O157:H7. Nucleic Acids Res 1998, 26:4196–4204.PubMedCrossRefGoogle Scholar
  35. 35.
    van Setten PA, van Hinsbergh VWM, van der Velden TJAN, et al.: Effects of TNFa on verocytotoxin cytotoxicity in purified human glomerular microvascular endothelial cells. Kidney Int 1997, 51:1245–1256.PubMedCrossRefGoogle Scholar
  36. 36.
    Simon M, Cleary TG, Hernandez JD, et al.: Shiga toxin 1 elicits diverse biologic responses in mesangial cells. Kidney Int 1998, 54:1117–1127.PubMedCrossRefGoogle Scholar
  37. 37.
    Isogai E, Isogai H, Kimura K, et al.: Role of tumor necrosis factor alpha in gnotobiotic mice infected with an Escherichia coli O157:H7 strain. Infect Immun 1998, 66:197–202.PubMedGoogle Scholar
  38. 38.
    Sakiri R, Ramegowda B, Tesh VL: Shiga toxin type 1 activates tumor necrosis factor-a gene transcription and nuclear translocation of the transcriptional activators nuclear factor-kB and activator protein-1. Blood 1998, 92:558–566. This study establishes that Shiga toxins not only have direct cytotoxic effects but can also induce host cytokine defenses. In a series of well-controlled experiments, the authors show an increase in TNF-a mRNA mediated by the nuclear translocation of transcriptional activators. This further contributes to our understanding of the pathogenesis of STEC.PubMedGoogle Scholar
  39. 39.
    Hughes AK, Stricklett PK, Kohan DE: Shiga toxin-1 regulation of cytokine production by human proximal tubule cells. Kidney Int 1998, 54:1093–1106.PubMedCrossRefGoogle Scholar
  40. 40.
    Louise CB, Tran MC, Obrig TG: Sensitization of human umbilical vein endothelial cells to Shiga toxin: involvement of protein kinase C and NF-kB. Infect Immun 1997, 65:3337–3344.PubMedGoogle Scholar
  41. 41.
    Proulx F, Turgeon JP, Litalien C, et al.: Inflammatory mediators in Escherichia coli O157:H7 hemorrhagic colitis and hemolytic-uremic syndrome. Pediatr Infect Dis J 1998, 17:899–904.PubMedCrossRefGoogle Scholar
  42. 42.
    van Setten PA, Hinsbergh VWM, van den Heuvel LPWJ, et al.: Monocyte chemoattractant protein-1 and interleukin-8 levels in urine and serum of patients with hemolytic uremic syndrome. Pediatr Res 1998, 43:759–767.PubMedCrossRefGoogle Scholar
  43. 43.
    Herlitz H, Petersson A, Sigström L, et al.: The arginine-nitric oxide pathway in thrombotic microangiopathy. Scand J Urol Nephrol 1997, 31:477–479.PubMedGoogle Scholar
  44. 44.
    Bitzan MM, Wang Y, Lin J, et al.: Verotoxin and ricin have novel effects on preproendothelin-1 expression but fail to modify nitric oxide synthase (ecNOS) expression and NO production in vascular endothelium. J Clin Invest 1998, 101:372–382.PubMedCrossRefGoogle Scholar
  45. 45.
    Gannon VPJ, D’Souza S, Graham T, et al.: Use of the flagellar H7 gene as a target in multiplex PCR assays and improved specificity in identification of enterohemorrhagic Escherichia coli strains. J Clin Microbiol 1997, 35:656–662.PubMedGoogle Scholar
  46. 46.
    Thompson CJ, Daly C, Barrett TJ, et al.: Insertion element IS3-based PCR method for subtyping Escherichia coli O157:H7. J Clin Microbiol 1998, 36:1180–1184.PubMedGoogle Scholar
  47. 47.
    Paton AW, Paton JC: Detection and characterization of Shiga toxigenic Escherichia coli by using multiplex PCR assays for stx1, stx2, eaeA, enterohemorrhagic E. coli hlyA, rfbO111 and rfbO157. J Clin Microbiol 1998, 36:598–602.PubMedGoogle Scholar
  48. 48.
    Desmarchelier PM, Bilge SS, Fegan N, et al.: A PCR specific for Escherichia coli O157 based on the rfb locus encoding O157 lipopolysaccharide. J Clin Microbiol 1998, 36:1801–1804.PubMedGoogle Scholar
  49. 49.
    Kehl KS, Havens P, Behnke CE, et al.: Evaluation of the Premier EHEC assay for detection of Shiga toxin-producing Escherichia coli. J Clin Microbiol 1997, 35:2051–2054.PubMedGoogle Scholar
  50. 50.
    Brewster JD, Mazenko RS: Filtration capture and immunoelectrochemical detection for rapid assay of Escherichia coli O157:H7. J Immunol Methods 1998, 211:1–8.PubMedCrossRefGoogle Scholar
  51. 51.
    Reymond D, Karmali MA, Clarke I, et al.: Comparison of the Western blot assay with the neutralizing-antibody and enzyme-linked immunosorbent assays for measuring antibody to Verocytoxin 1. J Clin Microbiol 1997, 35:609–613.PubMedGoogle Scholar
  52. 52.
    Karmali MA, Petric M, Bielaszewska M: Evaluation of a microplate latex agglutination method (Verotox-F assay) for detecting and characterizing Verotoxins (Shiga toxins) in Escherichia coli. J Clin Microbiol 1999, 37:396–399.PubMedGoogle Scholar
  53. 53.
    Johnson JL, Brooke CL, Fritschel SJ: Comparison of the BAX for screening/E. coli O157:H7 method with conventional methods for detection of extremely low levels of Escherichia coli O157:H7 in ground beef. Appl Environ Microbiol 1998, 64:4390–4395.PubMedGoogle Scholar
  54. 54.
    Entis P: Direct 24-hour presumptive enumeration of Escherichia coli O157:H7 in foods using hydrophobic grid membrane filter followed by serological confirmation: collaborative study. J AOAC Int 1998, 81:403–418.PubMedGoogle Scholar
  55. 55.
    Yoh M, Frimpong EK, Honda T: Effect of antimicrobial agents, especially fosfomycin, on the production and release of Vero toxin by enterohaemorrhagic Escherichia coli O157:H7. FEMS Immunol Med Microbiol 1997, 19:57–64.PubMedCrossRefGoogle Scholar
  56. 56.
    Izumikawa K, Hirakata Y, Yamaguchi T, et al.: Escherichia coli O157 interactions with human intestinal Caco-2 cells and the influence of fosfomycin. J Antimicrob Chemother 1998, 42:341–347.PubMedCrossRefGoogle Scholar
  57. 57.
    Tsuboi I, Ida H, Yoshikawa E, et al.: Antibiotic susceptibility of enterohemorrhagic Escherichia coli O157:H7 isolated from an outbreak in Japan in 1996. Antimicrob Agents Chemother 1998, 42:431–432.PubMedGoogle Scholar
  58. 58.
    Duncan SH, Flint HJ, Stewart CS: Inhibitory activity of gut bacteria against Escherichia coli O157 mediated by dietary plant metabolites. FEMS Microbiol Lett 1998, 164:283–288.PubMedCrossRefGoogle Scholar
  59. 59.
    Isogai E, Isogai H, Takeshi K, et al.: Protective effect of Japanese green tea extract on gnotobiotic mice infected with an Escherichia coli O157:H7 strain. Microbiol Immunol 1998, 42:125–128.PubMedGoogle Scholar
  60. 60.
    Zhao T, Doyle MP, Harmon BG, et al.: Reduction of carriage of enterohemorrhagic Escherichia coli O157:H7 in cattle by inoculation with probiotic bacteria. J Clin Microbiol 1998, 36:641–647.PubMedGoogle Scholar
  61. 61.
    Tauxe RV: Strategies for surveillance and prevention. Lancet 1998, 352(suppl_IV):10.CrossRefGoogle Scholar
  62. 62.
    Konadu EY, Parke JC Jr, Tran HT, et al.: Investigational vaccine for Escherichia coli O157: phase 1 study of O157 O-specific polysaccharide-Pseudomonas aeruginosa recombinant exoprotein A conjugates in adults. J Infect Dis 1998, 177:383–387.PubMedCrossRefGoogle Scholar
  63. 63.
    Acheson DWK, Levinson RK: Safe Eating. New York: Dell Publishing; 1998.Google Scholar
  64. 64.
    Swerdlow DL, Griffin PM: Duration of faecal shedding of Escherichia coli O157:H7 among children in day-care centres. Lancet 1997, 349:745–746.PubMedCrossRefGoogle Scholar

Copyright information

© Current Science Inc. 2000

Authors and Affiliations

  • Jenifer L. Jaeger
    • 1
  • David W. K. Acheson
    • 1
  1. 1.Division of Geographic Medicine and Infectious DiseasesNew England Medical CenterBostonUSA

Personalised recommendations